Why STAAR Surgical Stock Is Drawing Attention Now

STAAR Surgical (STAA) is back on investors’ radar after a volatile period, with the stock up over the past 3 months but down over the past month and past year.

Recent trading paints a mixed picture for STAAR Surgical, with the share price at $28.37 after a 90 day share price return of 58.94%, but a 5 year total shareholder return that declined 80.85%. This suggests near term momentum in contrast with a much weaker long term record.

If you are comparing STAAR Surgical with other opportunities in the sector, this could be a good moment to see what else is moving in healthcare AI and scan the 39 healthcare AI stocks

With STAAR Surgical stock up 58.94% over 90 days but still carrying a weak 5-year record and a small 4.6% discount to analyst targets, is there real upside left here or is the market already pricing in future growth?

Most Popular Narrative: 4.4% Undervalued

At $28.37, STAAR Surgical is priced slightly below the most followed fair value estimate of $29.67, so the current story hinges on how credible those forecasts look.

STAAR Surgical has significant cash reserves and no debt, providing a strong financial base to navigate the current challenges, reduce production outputs temporarily, and invest selectively in growth initiatives, potentially stabilizing earnings and providing upside if conditions improve.

Want to understand why this fair value sits above today’s STAAR Surgical share price? The narrative leans heavily on faster earnings progress, richer margins, and a future profit multiple that assumes investors keep paying a premium for growth. Curious which specific revenue and margin paths have to line up to support that valuation.

Result: Fair Value of $29.67 (UNDERVALUED)

However, STAAR Surgical still faces key risks, including weak consumer confidence in China and reliance on a single distributor there, which could disrupt revenue visibility.

Another Look At STAAR Surgical Stock: What P/S Is Saying

While the analyst narrative points to a fair value of $29.67, the current P/S of 4.9x for STAAR Surgical sits well above both peers at 1.9x and the US Medical Equipment industry at 2.7x, and also above an estimated fair ratio of 3.3x. That gap suggests investors are already paying up, so the key question is whether future execution will be strong enough to support this richer pricing.

Next Steps

With sentiment on STAAR Surgical clearly mixed, this is a moment to move quickly, review the underlying data, and weigh the 1 key reward

Looking for more investment ideas beyond STAAR Surgical?

STAAR Surgical may have caught your attention today, but your next strong opportunity could be sitting in plain sight if you widen the search with a few focused screens.

• Target resilience by zeroing in on companies that combine balance sheet strength with solid fundamentals using the solid balance sheet and fundamentals stocks screener (48 results).
• Hunt for mispriced quality by scanning the 47 high quality undervalued stocks, which filters for companies with strong cash flows at prices that may not fully reflect their fundamentals.
• Prioritize staying power by reviewing the 68 resilient stocks with low risk scores to see which stocks score well on stability so you are not relying on hope alone.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.